Keywords: Peroxisome proliferator-activated receptor gamma (PPARI3), Nuclear regulatory factor 2 (NRF2
), Oxidative stress, Developmental block, Maternal-to-zygotic transition.
Nuclear factor erythroid-related factor 2 (Nrf2
) is a transcription factor responsible for the regulation of cellular redox balance and protective antioxidant and phase II detoxification responses in mammals (17,18).
Next, nuclear factor erythroid 2-related factor 2 (Nrf2
) was knocked down with Nrf2
small interfering RNA (siRNA) to confirm the specific role of Nrf2
in mucin regulation of CUR in NCI-H292 cells.
LifeVantage will initially offer its complete TrueScience Beauty System - the company's popular line of Nrf2-enhanced skin care products - with its flagship Protandim Nrf2
Synergizer anticipated to follow in the near future.
They have shown for the first time that the transcription factor Nrf2
largely mediates the potentiating effect of plant polyphenols on 1,25D-induced differentiation in human AML cells.
The study focused on the role of two cell signaling pathways--KEAP1/ NRF2
and PI3K-which are known to be involved in adenocarcinomas.
In view of liraglutide's antioxidative stress activity, we speculated that it could activate the nuclear factor erythroid 2-related factor (Nrf2
)/heme oxygenase-1 (HO-1) pathway in the treatment of diabetes complicated with cerebral infarction.
is considered to be the main transcription factor of antioxidative stress [1, 2].
Nuclear factor erythroid 2-related factor 2 (Nrf2
), a redox-sensitive transcription factor, is bound to the negative regulator Kelch-like ECH-associated protein 1 (Keap1) in the cytoplasm and degraded by the ubiquitin-proteasome pathway in basal condition .
Immunohistochemical markers for G6PDH, 6PGL, 6PGDH, and NRF2
were assessed by a semiquantitative evaluation method as follows : 0: negative or weak immunostaining in <1% of the tumor; 1: focal expression in 1-10% of the tumor; 2: positive in 11%-50% of the tumor; and 3: positive in 51%-100% of the tumor.
indicated that the HER2-targeted therapeutic treatment promoted reactive oxygen species (ROS), glutathione (GSH) depletion, reduction in nuclear factor erythroid 2-related factor 2 (Nrf2
) levels, and inhibition of Nrf2
function in ovarian cancer cell lines .